Trokendi XR extended release capsules 25mg, 50mg, 100mg

Booth No: M426

Characteristic

Trokendi XR® is a novel extended-release formulation utilizing the Microtrol® delivery system. With its unique three-phase release mechanism, Trokendi XR® provides stable plasma drug concentrations, minimizing the fluctuations and side effects associated with immediate-release topiramate formulations. Under Taiwan’s National Health Insurance reimbursement scheme, it has been approved as a Category 2B new drug, and its reimbursed dosage strengths (25–100 mg) are priced more competitively than those of the originator.

According to the 2022 Taiwan Guidelines for the Preventive Treatment of Migraine, Trokendi XR® is recommended as a first-line option for both episodic and chronic migraine. Clinical evidence indicates that it reduces breakthrough migraine attacks caused by trough concentrations, allows better tolerability during titration to target doses, and improves patient adherence and treatment continuity. Real-world clinical experience in Taiwan has shown that nearly half of patients switching from TPM-IR to Trokendi XR® experienced a reduction in headache frequency, were able to tolerate higher daily doses, and reported significantly fewer cognitive side effects.